📰 Peter Ellmark News
Peter Ellmark News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Ellmark. Real-time updates on events, politics, business and more.
May 24, 2024
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confir...
May 23, 2024
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months)
May 5, 2021
Share: LUND, Sweden, May 5, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy. The published data show that mitazalimab activates dendritic cells and tumor-reactive T cells resulting in enhanced anti-tumor efficacy in combination with a model cancer vaccine. Title: The human anti-CD40 agonist antibody mitazalimab ...